Articles

A newly published clinical trial in Gut Microbes – a top journal reporting the latest science in microbiota – has confirmed that Kaneka Group / AB-Biotics’ AB21 probiotic formulation exhibits significant positive effects in COVID-19 outpatients.

A newly published clinical trial in Gut Microbes – a top journal reporting the latest science in microbiota – has confirmed that Kaneka Group / AB-Biotics’ AB21 probiotic formulation exhibits significant positive effects in COVID-19 outpatients.

AB-LIFE probiotic formulation has recently been approved by the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária, Anvisa) as a safe and efficient food supplement to help reduce cholesterol levels.

Frontiers has published the latest clinical data of AB-KOLICARE™, that shows quite promising results on infant colic. This probiotic formulation leads AB-BIOTICS pediatric line, containing two bacteria strains with a battery of benefits for babies.

Microbiome science keeps expanding and evolving at an accelerated rate. Scientists, healthcare professionals and consumers are progressively more aware of the microbiota, and how its modulation can have a beneficial impact on health status.

Last 8th of April, the third scientific-practical conference dedicated to the memory of V.V.Murashko took place in Moscow, Russia. The program contained extended lectures around lipidology, cardiology, gastroenterology and gerontology

Irritable bowel syndrome (IBS) is a very common functional gastrointestinal disorder that affects around 580 million people worldwide. It is a major women’s health issue since 2 out of 3 individuals who report IBS in the community are female.

The latest consensus guidelines (Rome IV) define IBS as: “A gut-brain disorder characterized by recurrent abdominal pain associated to changes in frequency or appearance of stools at least 1 day per week for the last 3 months” 1

IBS symptoms include abdominal pain, discomfort , bloating or distension and gut-specific anxiety.

All these features interfere with the daily life of many patients, having a significant detrimental effect in their quality of life.

Immediately after birth, the gut of new-borns is colonized by microbes, conforming a simple ecosystem. This group of microorganisms (known as gut microbiota) will change during a lifetime,

LipiGO® contains a completely natural extract from the yeast Saccharomyces cerevisiae (BCGG™) and acts in the gut without disturbing intestinal flora. It helps to reach a healthy weight and prevents from the rebound effect.

L. plantarum DR7 is a probiotic strain with multiple proven therapeutic benefits, and great potential for immune health. Its most remarkable clinical trial tests the probiotic as a treatment for Upper Respiratory Tract Infections (URTIs).